Dossier assessment
Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with relapsing forms of multiple sclerosis (RMS)
Result of dossier assessment:
- Adults with RMS who have not yet received disease-modifying therapy or adult patients with non-highly active disease pretreated with disease-modifying therapy: added benefit not proven.
- Adults with RMS with highly active disease despite treatment with disease-modifying therapy: added benefit not proven.
Project details
- Project no.
- A21-83
- Commission
- Commission awarded on 15.06.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed